^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    letrozole

    i
    Other names: CGP 20267, CGS 20267, CGS20267
    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    6d
    A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=4800, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tamoxifen • letrozole
    7d
    A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    ER positive • HER-2 negative • PIK3CA mutation • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole • Itovebi (inavolisib)
    8d
    OBU-BC-II-164: Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=100, Enrolling by invitation, Peking University | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    EndoPredict®
    |
    letrozole • AiRuiKang (dalpiciclib)
    12d
    OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=510, Recruiting, Olema Pharmaceuticals, Inc. | N=370 --> 510
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ESR1 mutation
    |
    fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)
    12d
    FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov)
    P2/3, N=260, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    ER positive • MSI-H/dMMR
    |
    Tyvyt (sintilimab) • letrozole • triptorelin • megestrol
    13d
    HCC 21-208: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov)
    P1, N=50, Recruiting, Finn, Olivera, PhD | Trial completion date: Aug 2028 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    tamoxifen • letrozole • anastrozole • exemestane • Hiltonol (poly-ICLC)
    13d
    Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruth O'Regan | Trial completion date: Jan 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    13d
    Protective Effects of Hesperidin on Letrozole-Induced Neurotoxicity: Involvement of Oxidative Stress, Apoptotic Signaling, and Inflammation. (PubMed, J Biochem Mol Toxicol)
    These findings indicate that hesperidin confers neuroprotection by restoring redox balance, regulating apoptosis, and suppressing inflammation in letrozole-induced neurotoxicity. Further studies are warranted to elucidate the precise molecular mechanisms and potential therapeutic applications of hesperidin in letrozole-induced neurotoxicity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    HR positive
    |
    letrozole
    14d
    Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report. (PubMed, Front Oncol)
    At last follow-up (OS: 108 months), she maintained SD with minimal toxicity. This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.
    Journal
    |
    ER (Estrogen receptor)
    |
    HR positive
    |
    letrozole • megestrol
    14d
    2022P002556-ENC-MONALEESA-2: Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=2495, Completed, Shirley Vichy Wang | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Kisqali (ribociclib) • letrozole
    14d
    FELINE: Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (clinicaltrials.gov)
    P2, N=121, Active, not recruiting, Qamar Khan | Trial completion date: Apr 2023 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • letrozole
    16d
    GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Gynecologic Oncology Group | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib) • letrozole